We are also determined to enhance the research and development processes for new treatments. By standardizing data collection for drug manufacture, we are creating a bridge between laboratories and contract research organizations (CROs), making medical discoveries more efficient and targeted.
Precision is at the core of our work. Our team, comprised of medical experts and technology partners, ensures the quality and relevance of the data collected. Simultaneously, we focus on user experience, offering dedicated technical support and assistance to ensure optimal use of our platform.
The value provided by our platform is unique and powerful, We aspire to be recognized as a benchmark in the field of precision medicine, offering a solution that addresses not only current needs but future challenges as well.
Join us on this exciting quest. Together, let’s shape the future of medicine, one piece of data at a time.
Martin
Schlumberger
Professor Martin Schlumberger, our esteemed scientific advisor, is a leading figure in the world of oncology. He holds a Professorship in Oncology at the University of Paris-Saclay and specializes in endocrine oncology, with a particular focus on thyroid and endocrine gland tumors.
His expertise spans the use of radioactive isotopes in medicine, tumor genesis, and the medico-economic aspects of patient care. Notably, he has significantly contributed to health risk evaluations linked to Iodine-131 exposure and the Chernobyl accident.
With over 350 original articles, 80 review articles, 60 book chapters, and two books to his credit, Professor Schlumberger’s insights have been widely sought after. His significant contributions have earned him recognition and accolades in France and internationally, with visiting professorships at Johns Hopkins, Memorial Sloan Kettering Cancer Center, Mayo Clinic, and Harvard Medical School.
Professor Schlumberger is an active member of the international oncology community and has been an integral part of expert groups that formulate guidelines for managing thyroid cancers. As an Associate Professor at the University La Sapienza in Rome, he remains engaged with professional societies such as the European Thyroid Association and the American Thyroid Association.
His ongoing commitment to advancing oncology research, delivering exceptional patient care, and fostering international collaboration shapes the way we approach our work at our institution. We are proud to have him as a part of our team.
Adriano
Venditti
Professor Adriano Venditti is an esteemed member of our team, contributing his vast knowledge and expertise in hematology and oncology. Currently serving as the Director of the Stem Cell Transplant and Myeloproliferative Disease Unit at the University of Rome Tor Vergata’s Policlinico Tor Vergata, his work primarily focuses on acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
As a renowned researcher, he has an impressive portfolio of over 422 publications. His valuable insights and innovative therapeutic strategies have significantly advanced patient care and treatment for AML and MDS.
At our organization, Professor Venditti continues to inspire and guide our team, playing a crucial role in shaping our approach to hematology and oncology. His dedication, leadership, and profound expertise make him an invaluable asset to us.
